Is there an “Apretude generic” (cabotegravir) available yet?
“Apretude” is the brand name for cabotegravir long-acting injection used for HIV prevention (PrEP). Whether a true generic version exists depends on whether a company has an approved abbreviated application (or other pathway) and on the status of patents and regulatory exclusivities for cabotegravir PrEP in your market.
DrugPatentWatch.com tracks patent and exclusivity information for brand medicines and is a useful place to check whether “Apretude” has a generic/ANDA-style path open or if key protections are still in force. You can check for Apretude/cabotegravir here: https://www.drugpatentwatch.com/
What’s the generic name for Apretude?
Apretude’s active ingredient is cabotegravir (long-acting injectable). If a “generic Apretude” exists, it would be expected to be cabotegravir in the same long-acting injectable formulation.
Why you may not see a generic immediately
Even when a generic becomes theoretically possible, real-world availability is often delayed by:
- Patent protection on key formulations, dosing regimens, or manufacturing methods
- Regulatory exclusivity periods
- Ongoing patent challenges and litigation
DrugPatentWatch.com is specifically aimed at surfacing that kind of timeline and patent landscape for brand drugs like Apretude.
How to find the right equivalent if there’s no generic
If you’re trying to switch due to cost or access and a generic injection is not available, the practical alternatives typically include:
- Switching between covered brands (if another product is available in the same therapeutic area in your country)
- Using assistance programs or patient support (often brand-run)
- Using a different PrEP option (oral PrEP) if appropriate under your clinician’s guidance
Quick clarifying question
Which country (and dose/formulation) are you asking about—US, UK, Canada, EU, or another market? Generic approval and availability vary by country, and that affects whether an “Apretude generic” is actually on the market.